JYPC(SZ:002198) Zheng Quan Zhi Xing·2025-05-11 08:10Core Viewpoint The Guangdong Jiaying Pharmaceutical Co., Ltd. is preparing for its 2024 Annual General Meeting, focusing on various proposals including financial reports, profit distribution plans, and corporate governance matters. Group 1: Meeting Details - The meeting is scheduled for May 16, 2025, at 14:30 in Meizhou, Guangdong Province [5] - Attendees will include shareholders, company directors, supervisors, senior management, and invited guests [5] Group 2: Proposals for Review - Proposal 1: Review of the 2024 Annual Report and its summary [6] - Proposal 2: Review of the 2024 Financial Settlement Report, audited by Zhonghua Accounting Firm [7] - Proposal 3: Profit distribution plan for 2024, which proposes no cash dividends or stock bonuses [9][11] - Proposal 4: Review of the 2024 Board of Directors' Work Report, highlighting operational achievements and challenges [14] - Proposal 5: Review of the 2024 Supervisory Board's Work Report, detailing compliance and oversight activities [32] - Proposal 6: Confirmation of 2024 director remuneration and proposal for 2025 remuneration [36] - Proposal 7: Request for a comprehensive credit limit of up to RMB 200 million from banks for operational needs [37] - Proposal 8: Review of daily related party transactions for 2024 and projections for 2025 [40] Group 3: Financial Performance and Strategy - The company reported a net profit of RMB 16,346,842.23 for 2024, with no cash dividends proposed due to financial constraints and strategic investments [9][11] - The company aims to enhance its product portfolio and reduce reliance on a single product line, particularly in response to market fluctuations affecting its main products [11][12] - The company plans to invest in research and development to diversify its offerings and improve market competitiveness [29][30] Group 4: Corporate Governance and Compliance - The company has established a robust internal control system to ensure compliance with laws and regulations, maintaining transparency and protecting shareholder interests [33][35] - The Supervisory Board has actively monitored the company's operations, ensuring adherence to legal and regulatory standards [32][34]